Avalo Therapeutics, Inc. 8-K

What Happened
Avalo Therapeutics, Inc. (filed Form 8-K, Item 5.02) announced on March 23, 2026 that board members Dr. Jonathan Goldman and Mitchell Chan each notified the company they will not stand for re‑election at the company’s 2026 Annual Meeting of Stockholders. Both will continue to serve on the board until the 2026 Annual Meeting. The company said their decisions are not due to any disagreement with Avalo on operations, policies or practices, and the Board expressed appreciation for their service.

Key Details

• Notification date: March 23, 2026.
• Directors: Dr. Jonathan Goldman and Mitchell Chan.
• Status: Each will remain on the Board until the 2026 Annual Meeting but will not seek re-election.
• Company note: Decisions are not the result of any disagreement with Avalo over operations, policies or practices.

Why It Matters
Board departures can affect corporate governance and investor oversight because they may change board composition and committees after the 2026 Annual Meeting. Investors should watch upcoming proxy materials and company announcements for information about board nominees, any announced replacements, and potential changes to board committee membership or governance that could follow these departures.